Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12760083-B2

Patent

Publication Date

2026-10-13

Expiration Date


Abstract

A non-naturally occurring polynucleotide encoding a miRNA that inhibits the expression of an immune checkpoint protein. The polynucleotide may further encode a chimeric receptor, a cytokine, and/or a cell tag. A vector comprising the aforementioned polynucleotide. A modified immune effector cell comprising the aforementioned polynucleotide. Compositions and kits comprising the aforementioned polynucleotide and/or cell. A method for treating a subject suffering from a disease or disorder, comprising administering the aforementioned cell to a subject in need thereof. The use of the aforementioned cell in the manufacture of a medicament for the treatment of a disease or disorder. A method for the detection of a disease or disorder associated with the overexpression of an antigen in a subject. A method for the treatment of a disease or disorder comprising the serial administration of polynucleotides encoding a chimeric antigen receptor or a cell comprising the same.

Core Innovation

The disclosure describes a non-naturally occurring polynucleotide comprising a first nucleic acid sequence comprising SEQ ID NO: 179, a second nucleic acid sequence comprising SEQ ID NO: 180, and a third nucleic acid sequence encoding a chimeric antigen receptor. The chimeric antigen receptor comprises a variable light chain domain comprising SEQ ID NO: 387 and a variable heavy chain domain comprising SEQ ID NO: 349, targeted to hROR1 or EGFRvIII. The construct framework optionally incorporates spacer, transmembrane, intracellular signaling, and signal peptide domains alongside anti-ROR1 variable domain variants and linked single-chain variable fragments.

The construct framework incorporates expression cassettes with synthetic introns generating checkpoint-targeting engineered miRNAs directed against targets including PD-1 and TIGIT. The disclosure further encompasses modified immune effector cells, vectors including viral vectors and transposon systems such as Sleeping Beauty, cytokine components including an IL-15/IL-15Ralpha fusion, and a truncated HER1 cell tag. In addition, ligand-inducible EcR/RXR gene switches regulate chimeric antigen receptor, cytokine, and cell-tag expression to achieve simultaneous receptor expression and miRNA-mediated checkpoint gene silencing.

Reported experimental studies demonstrate reduced PD-1 and TIGIT expression, suppressed target cell growth in co-culture systems, increased CAR-T cytotoxicity and cytokine expression, lower tumor-associated bioluminescent signals, and improved tumor control. In addition, sequencing evaluations indicate preferential production of intended guide miRNAs, limited passenger-miRNA generation, and no detectable global disruption of endogenous host miRNAs.

Claims Coverage

The claims identify one independent claim comprising two inventive features directed to a sequence-defined polynucleotide construct encoding checkpoint-inhibitory miRNAs and a chimeric antigen receptor.

Polynucleotide containing two specified nucleic acid sequences

The non-naturally occurring polynucleotide comprises a first nucleic acid sequence comprising SEQ ID NO: 179 and a second nucleic acid sequence comprising SEQ ID NO: 180.

Chimeric antigen receptor with specified variable light and heavy chain domains

The polynucleotide comprises a third nucleic acid sequence encoding a chimeric antigen receptor with a variable light chain domain comprising SEQ ID NO: 387 and a variable heavy chain domain comprising SEQ ID NO: 349.

The independent claim covers all elements of the claim defining the polynucleotide containing the two specified nucleic acid sequences and encoding the sequence-defined CAR, with dependent claims extending to encoded cytokines, cell tags, vectors, modified immune effector cells, compositions, and kits.

Stated Advantages

The described studies report reduced PD-1 and TIGIT expression, as well as lower tumor-associated bioluminescent signal compared with CAR-only cells.

The described studies report increased CAR-T cytotoxicity and cytokine expression, and improved tumor control.

Sequencing indicates preferential production of intended guide miRNAs, limited passenger-miRNA generation, and no detectable global disruption of endogenous miRNAs.

Documented Applications

Treatment of antigen-expressing cancers and antigen-overexpressing diseases using modified immune effector cells, including serial or personalized CAR-T cell administration.

Therapeutic regimens incorporating optional lymphodepletion or combination therapy.

Polynucleotide delivery to generate in vitro modified immune effector cells using electroporation, viral vectors, or transposon systems such as Sleeping Beauty.

High-throughput cell handling, scale-up, and rapid or decentralized CAR-T cell manufacturing.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.